Status:
UNKNOWN
Role of HIF-1α in Skeletal Muscle Aging
Lead Sponsor:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Conditions:
Sarcopenia
Eligibility:
All Genders
18-90 years
Brief Summary
Deficits in skeletal muscle function exist during aging and muscular dystrophy, and suboptimal function has been related to factors such as atrophy, excessive inflammation and fibrosis. Sarcopenia is ...
Detailed Description
Deficits in skeletal muscle function exist during aging and muscular dystrophy, and suboptimal function has been related to factors such as atrophy, excessive inflammation and fibrosis. Sarcopenia is ...
Eligibility Criteria
Inclusion
- Sarcopenic patients (measured by DXA) affected by hip osteoarthritis, developmental dysplasia of the hip or hip fracture and undergoing hip replacement surgery (for the sarcopenic group)
- Patients affected by traumatic ACL tears and undergoing ACL reconstruction surgery (for the control group)
- Patients between 18 and 35 years old (for the control group)
- Patients between 65 and 90 years old (for the sarcopenic group)
- 18 ≤ Body Mass Index (BMI) ≤ 30 kg/m2
Exclusion
- Diseases that can affect bone or muscle metabolism
- Pharmacological therapies that can interact with bone or muscle metabolism
- Bone metastases
- Bone infections
- HIV, hepatitis B virus, hepatitis C virus or Treponema pallidum positivity
- BMI ≥30kg/m2
Key Trial Info
Start Date :
January 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 26 2020
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03371134
Start Date
January 10 2018
End Date
July 26 2020
Last Update
December 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.